Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1048-1053

  Richey, S L ^a   Culp, S H ^a   Jonasch, E ^a   Corn, P G ^a   Pagliaro, L C ^a   Tamboli, P ^a   Patel, K K ^b   Matin, S F ^a   Wood, C G ^a   Tannir, N M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytoreductive nephrectomy; Prognosis; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CALCIUM; CAPECITABINE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MORTALITY; NEPHRECTOMY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 79955489863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq563     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society 2009; http://www.cancer.org/acs/groups/content/@nho/documents/document/500809webpdf.pdf (8 September 2010, date last accessed).
2. Lam JS, Shvarts O, Leppert JT et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173(6): 1853-1862. Review.
3. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358(9286): 966-970.
4. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001; 345(23): 1655-1659.
5. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171(3): 1071-1076.
6. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
7. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
8. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
9. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111.
10. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
11. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-5428.
12. Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009; 27: 15s (Abstr 5021 from 2009 ASCO Annual Meeting).
13. Culine S, Bekradda M, Kramar A et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 1998; 83(12): 2548-2553.
14. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22(3): 454-463.
15. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20(9): 2376-2381.
16. Epstein J, Sauter G. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press 2004.
17. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Manual, 6th edition. New York: Springer-Verlag 2002.
18. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289-296.
19. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-5799.
20. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renalcell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10(8): 757-763.
21. Knox JJ, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007; 25: 237s. (Suppl; Abstr 5011).
22. Beck J, Procopio G, Verzoni E et al. Large open-label, non-comparative, clinical experience trial of the multi-targeted kinase inhibitor sorafenib in European patients with advanced RCC. J Clin Oncol 2008; 26: 16021. (Meeting Abstr).
23. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8): 2530-2540.
24. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110(3): 543-550.
25. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97(12): 2995-3002.
26. Leibovich BC, Han KR, Bui MH et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98(12): 2566-2575.
27. Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174(5): 1759-1763; discussion 1763.
28. Park JH, Kim SH, Han JK et al. Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil. Cardiovasc Intervent Radiol 1994; 17(6): 323-327.
29. Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distantmetastases. BJU Int 2001; 87: 312-315.
30. Munro NP, Woodhams S, Nawrocki JD et al. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 2003; 92(3): 240-244.
31. Serafin Z, Karolkiewicz M, Strześniewski P et al. Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control. Med Sci Monit 2007; 13 (Suppl 1): 98-104.
32. Maxwell NJ, Saleem Amer N, Rogers E et al. Renal artery embolisation in the palliative treatment of renal carcinoma [erratum appears in Br J Radiol 2007; 80 (958): 853]. Br J Radiol 2007; 80(950): 96-102.